Company intelligence / Profile preview

PredxBio

Pittsburgh, Pennsylvania, United Statespredxbio.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

PredxBio develops explainable AI-powered spatial analytics software platforms that help decipher complex cancer biology to improve outcomes for immunotherapy patients. Their solutions accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapy options, and improve workflows. The company has completed engagements with early paying customers including pharmaceutical partners using their technology to assess treatment response in immunotherapy settings

Therapeutic areas: Oncology
Industry: Pathology

Partnerships

Early engagements with pharmaceutical companies as clients/users of the technology for assessing treatment response in immunotherapy trials. Specific partner names not disclosed.

Beyond the preview

Go deeper on PredxBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PredxBio.

Explore the full profile